iECURE
Bradley Dickerson currently serves as the Vice President of Project Management & Patient Advocacy at iECURE, inc., a position held since February 2022. Prior to this role, Bradley was the President of BJD Life Science Consulting from September 2021 to February 2022, and the Chief Commercial Officer at Palvella Therapeutics from October 2020 to August 2021, where responsibilities included building the commercial organization for new treatments in rare genodermatoses. Bradley's extensive experience also includes positions such as General Manager Americas at Aurinia Pharmaceuticals, where efforts focused on launch readiness and market access strategies, and senior roles at RX Crossroads Specialty Solutions, Shire (formerly NPS Pharmaceuticals), NPS Pharmaceuticals, ViroPharma Incorporated, and Wyeth, which involved leadership in market access, patient services, and commercialization of pharmaceutical products. Bradley holds a Bachelor of Arts degree in Management and Business Administration from Gettysburg College, earned between 1997 and 2001.
iECURE
1 followers
iECURE is a gene editing company focused on developing therapies that utilize mutation-agnostic in vivo gene insertion, or knock-in, editing for the treatment of liver disorders with significant unmet need. We believe our approach has the potential to replace and restore the function of a dysfunctional gene by knocking-in a healthy copy, regardless of mutation, to offer durable gene expression and long-term, potentially curative, therapeutic benefit. Our management team has extensive experience in executing global orphan drug and gene therapy clinical trials and successfully commercializing multiple products. We intend to leverage our team’s core strength in research and development strategy to identify what we believe to be the most suitable target and modality for our product candidates to address particular liver diseases. We are collaborating with the University of Pennsylvania’s Gene Therapy Program, or GTP, led by James M. Wilson, M.D., Ph.D., to utilize GTP’s world-class translational expertise and infrastructure, which has helped generate our initial pipeline of potential product candidates.